Business
BioElectronics’ RecoveryRx Pain Relief Device Receives Clearance from Cofepris, Launching Distribution in Mexico
BioElectronics’ RecoveryRx Pain Relief Device Receives Clearance from Cofepris, Launching Distribution in Mexico.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n FREDERICK, MD, March 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ (OTC: BIEL) today announced its distribution partner in Mexico has received authorization from Mexican FDA (Cofepris), which allows for the importation of the RecoveryRx® device into Mexico.e Novro Med S.A. de C.V. has contracted for the exclusive distribution rights for RecoveryRx® in Mexico.  It is expected that they will receive their initial stocking order during the 2nd quarter, 2022.   “After several months of working with Cofepris, we can proudly announce we have obtained the regulatory approval for RecoveryRx®.  We are very excited that we can bring this drug-free pain therapy device to patients in Mexico.  We look forward to working with BioElectronics to improve patient care in Mexico,” said Marcela Flores, General Manager of Novro Med S.A de C.V.   About Novro Med S.A. de C.V.: Novro Med S.A. de C.V. is managed by Global Tech which imports, distributes, and markets medical devices and other disposable medical items in Mexico.  They have more than18 years of experience in the Mexican market.  Their focus is orthopedics, implants, neurosurgery, biological, protection and neuromonitoring.  For more information, visit www.globaltech.com.mx  About BioElectronics:  BioElectronics Corporation is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx® Devices for post-operative pain and wound care.  For more information, visit www.bielcorp.com   Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered...